CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences introduces a novel ferritin-based delivery system for small interfering RNA (siRNA) targeting ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary ...

Previous work uncovered the role of the complement system in neuroinflammation and synaptic loss in neurodegenerative disorders such as Alzheimer’s disease (AD). The third component, C3, central in ...

The double-stranded RNA is processed by an RNase III family enzyme Dicer, resulting in the generation of an siRNA, a 21–23-nucleotide (nt) RNA duplex, composed of a 19-mer sequence with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its ...